ACB Research | Milton Maxwell

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q3 '26

Reaffirms exits, eyes new markets

2/3/26Feb 3, 2026

Q&A reinforced the prepared pivot from Canadian consumer and plant propagation, with Miguel Martin stressing flower reallocation to international medical boosts margins without ruling out full rec exit. Australia premiumization drew no disruption concerns, just accretive upside. Management disclosed eyeing Switzerland, Austria, France, Ukraine, and Turkey entries, plus majority self-production (near 100%) of international sales via GMP facilities. Guidance math probed but affirmed strong Q4 medical to hit full-year targets. Exits sharpen focus. Confident tone signals watch on divestitures, M&A, and new-market traction.

Key Stats

Market Cap

312.86M

P/E (TTM)

-

Basic EPS (TTM)

-0.73

Dividend Yield

0%

About

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants. It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.

CEO

Mr. Miguel Martin

IPO

7/15/2014

Website

https://www.auroramj.com

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic